Natera, Inc. (NASDAQ:NTRA) Shares Sold by Picton Mahoney Asset Management

Picton Mahoney Asset Management cut its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 2.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 95,390 shares of the medical research company's stock after selling 2,439 shares during the period. Picton Mahoney Asset Management owned about 0.07% of Natera worth $15,100,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of NTRA. Blue Trust Inc. lifted its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Covestor Ltd lifted its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after acquiring an additional 95 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares in the last quarter. Finally, Principal Securities Inc. lifted its position in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 6,000 shares of Natera stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the transaction, the insider now directly owns 143,768 shares in the company, valued at approximately $20,600,516.72. This trade represents a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 669 shares of Natera stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares in the company, valued at $18,217,063.20. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 298,946 shares of company stock worth $47,803,462 in the last ninety days. 7.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. Guggenheim boosted their price objective on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research report on Friday, January 17th. JPMorgan Chase & Co. boosted their price objective on Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. Royal Bank of Canada began coverage on Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target for the company. Robert W. Baird increased their price target on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Finally, BTIG Research reissued a "buy" rating on shares of Natera in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $178.12.

Natera Trading Up 3.1 %

Shares of NASDAQ NTRA traded up $4.59 during midday trading on Wednesday, hitting $150.87. The company's stock had a trading volume of 2,162,925 shares, compared to its average volume of 1,346,669. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business's 50 day moving average is $162.76 and its two-hundred day moving average is $149.26. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The firm has a market cap of $20.40 billion, a P/E ratio of -85.72 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.